WO2006091720A2
(en)
*
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
US7321033B2
(en)
|
2001-11-27 |
2008-01-22 |
Anadys Pharmaceuticals, Inc. |
3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
|
US7030129B2
(en)
*
|
2002-02-22 |
2006-04-18 |
3M Innovative Properties Company |
Method of reducing and treating UVB-induced immunosuppression
|
EP2572715A1
(en)
*
|
2002-12-30 |
2013-03-27 |
3M Innovative Properties Company |
Immunostimulatory Combinations
|
US7375180B2
(en)
*
|
2003-02-13 |
2008-05-20 |
3M Innovative Properties Company |
Methods and compositions related to IRM compounds and Toll-like receptor 8
|
EP1599726A4
(en)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
|
EP1601365A4
(en)
|
2003-03-04 |
2009-11-11 |
3M Innovative Properties Co |
PROPHYLACTIC TREATMENT OF UV-INDUCED EPIDERMAL NEOPLASIA
|
US7179253B2
(en)
|
2003-03-13 |
2007-02-20 |
3M Innovative Properties Company |
Method of tattoo removal
|
CA2518282C
(en)
*
|
2003-03-13 |
2012-11-06 |
3M Innovative Properties Company |
Methods of improving skin quality
|
US20040192585A1
(en)
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
WO2004091500A2
(en)
*
|
2003-04-10 |
2004-10-28 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
WO2005011629A1
(en)
*
|
2003-07-31 |
2005-02-10 |
3M Innovative Properties Company |
Bioactive compositions comprising triazines
|
CA2535117A1
(en)
|
2003-08-12 |
2005-03-03 |
3M Innovative Properties Company |
Oxime substituted imidazo-containing compounds
|
WO2005018574A2
(en)
*
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Immunostimulatory combinations and treatments
|
EP1658076B1
(en)
|
2003-08-27 |
2013-03-06 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
CA2537763A1
(en)
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for cd5+ b cell lymphoma
|
AP2006003542A0
(en)
|
2003-09-05 |
2006-04-30 |
Anadys Pharmaceuticals Inc |
Administration of TLR7 ligands and prodrugs for treatment of infection by hepatitis C virus.
|
US20050059072A1
(en)
*
|
2003-09-17 |
2005-03-17 |
3M Innovative Properties Company |
Selective modulation of TLR gene expression
|
EP1673087B1
(en)
|
2003-10-03 |
2015-05-13 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
CA2543685A1
(en)
*
|
2003-10-31 |
2005-05-12 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
US8598192B2
(en)
|
2003-11-14 |
2013-12-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazoquinolines
|
US7897767B2
(en)
|
2003-11-14 |
2011-03-01 |
3M Innovative Properties Company |
Oxime substituted imidazoquinolines
|
RU2409576C2
(ru)
|
2003-11-25 |
2011-01-20 |
3М Инновейтив Пропертиз Компани |
Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
WO2005055932A2
(en)
*
|
2003-12-02 |
2005-06-23 |
3M Innovative Properties Company |
Therapeutic combinations and methods including irm compounds
|
EP1701955A1
(en)
|
2003-12-29 |
2006-09-20 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
WO2005067500A2
(en)
*
|
2003-12-30 |
2005-07-28 |
3M Innovative Properties Company |
Enhancement of immune responses
|
US8735421B2
(en)
|
2003-12-30 |
2014-05-27 |
3M Innovative Properties Company |
Imidazoquinolinyl sulfonamides
|
CA2559863A1
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
US20070166384A1
(en)
*
|
2004-04-09 |
2007-07-19 |
Zarraga Isidro Angelo E |
Methods , composition and preparations for delivery of immune response modifiers
|
CN101426524A
(zh)
*
|
2004-04-28 |
2009-05-06 |
3M创新有限公司 |
用于粘膜接种疫苗的组合物和方法
|
ES2560449T3
(es)
|
2004-05-28 |
2016-02-19 |
Oryxe |
Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
EP1758916B1
(en)
|
2004-06-07 |
2012-11-21 |
Anadys Pharmaceuticals, Inc. |
3-BETA-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
WO2006065280A2
(en)
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
US7897609B2
(en)
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US8026366B2
(en)
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
EP1786450A4
(en)
*
|
2004-08-27 |
2009-11-11 |
3M Innovative Properties Co |
HIV IMMUNOSTIMATORY COMPOSITIONS
|
WO2006042254A2
(en)
*
|
2004-10-08 |
2006-04-20 |
3M Innovative Properties Company |
Adjuvant for dna vaccines
|
DK2561872T3
(en)
|
2004-12-17 |
2014-12-08 |
Anadys Pharmaceuticals Inc |
3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED 3H-OXAZOLO- [4,5-d] PYRIMIDIN-2-ON COMPOUNDS AND PRODRUGS THEREOF
|
JP5313502B2
(ja)
|
2004-12-30 |
2013-10-09 |
スリーエム イノベイティブ プロパティズ カンパニー |
置換キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
|
US8461174B2
(en)
|
2004-12-30 |
2013-06-11 |
3M Innovative Properties Company |
Treatment for cutaneous metastases
|
AU2005322898B2
(en)
|
2004-12-30 |
2011-11-24 |
3M Innovative Properties Company |
Chiral fused (1,2)imidazo(4,5-c) ring compounds
|
US9248127B2
(en)
|
2005-02-04 |
2016-02-02 |
3M Innovative Properties Company |
Aqueous gel formulations containing immune response modifiers
|
US7968563B2
(en)
|
2005-02-11 |
2011-06-28 |
3M Innovative Properties Company |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
WO2006091517A2
(en)
|
2005-02-18 |
2006-08-31 |
Novartis Vaccines And Diagnostics Inc. |
Immunogens from uropathogenic escherichia coli
|
PL2351772T3
(pl)
|
2005-02-18 |
2017-01-31 |
Glaxosmithkline Biologicals Sa |
Białka i kwasy nukleinowe z bakterii Escherichia coli związanej z zapaleniem opon mózgowo-rdzeniowych/posocznicą
|
US7943636B2
(en)
|
2005-04-01 |
2011-05-17 |
3M Innovative Properties Company |
1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
AU2006232377A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
WO2006137953A1
(en)
|
2005-04-01 |
2006-12-28 |
The Regents Of The Univerisity Of California |
Phosphono-pent-2-en-1-yl nucleosides and analogs
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
EP2614709A1
(en)
|
2005-07-18 |
2013-07-17 |
Novartis AG |
Small animal model for HCV replication
|
WO2007041632A2
(en)
*
|
2005-09-30 |
2007-04-12 |
Scynexis, Inc. |
Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
|
US8329658B2
(en)
|
2005-09-30 |
2012-12-11 |
Scynexis, Inc. |
Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
|
ES2420829T3
(es)
|
2005-11-04 |
2013-08-27 |
Novartis Vaccines And Diagnostics S.R.L. |
Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
|
US20110180430A1
(en)
|
2005-11-04 |
2011-07-28 |
Novartis Vaccines And Diagnostics Srl |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
DK1951299T3
(da)
|
2005-11-04 |
2012-04-02 |
Novartis Vaccines & Diagnostic |
Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere
|
EP2377552A3
(en)
|
2005-11-04 |
2013-05-15 |
Novartis Vaccines and Diagnostics S.r.l. |
Influenza vaccines with reduced amount of emulsion adjuvant
|
CA2630463C
(en)
|
2005-11-21 |
2015-01-06 |
Anadys Pharmaceuticals, Inc. |
Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-one
|
NZ570106A
(en)
|
2006-01-27 |
2012-04-27 |
Novartis Vaccines & Diagnostic |
Influenza vaccines containing hemagglutinin and matrix proteins
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
US8063063B2
(en)
*
|
2006-03-23 |
2011-11-22 |
Novartis Ag |
Immunopotentiating compounds
|
CA2647100A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Methods for the preparation of imidazole-containing compounds
|
ATE539079T1
(de)
*
|
2006-03-23 |
2012-01-15 |
Novartis Ag |
Imidazochinoxalinverbindungen als immunmodulatoren
|
EP2382987A1
(en)
|
2006-03-24 |
2011-11-02 |
Novartis Vaccines and Diagnostics GmbH |
Storage of influenza vaccines without refrigeration
|
US20100285062A1
(en)
|
2006-03-31 |
2010-11-11 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
EP2007789B1
(en)
|
2006-04-11 |
2015-05-20 |
Novartis AG |
Spirocyclic HCV/HIV inhibitors and their uses
|
CL2007001427A1
(es)
*
|
2006-05-22 |
2008-05-16 |
Novartis Ag |
Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
|
EP2054431B1
(en)
|
2006-06-09 |
2011-08-31 |
Novartis AG |
Conformers of bacterial adhesins
|
US7709448B2
(en)
|
2006-06-22 |
2010-05-04 |
Anadys Pharmaceuticals, Inc. |
Prodrugs of 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
|
US7906506B2
(en)
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
BRPI0714831A2
(pt)
*
|
2006-07-18 |
2013-04-02 |
Anadys Pharmaceuticals Inc |
composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
JP5954921B2
(ja)
|
2006-09-11 |
2016-07-20 |
ノバルティス アーゲー |
卵を使用しないインフルエンザウイルスワクチンの作製
|
BRPI0717741A2
(pt)
*
|
2006-10-17 |
2014-04-08 |
Anadys Pharmaceuticals Inc |
Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
|
US7576057B2
(en)
|
2006-11-20 |
2009-08-18 |
Scynexis, Inc. |
Cyclic peptides
|
US20110045022A1
(en)
|
2006-12-06 |
2011-02-24 |
Theodore Tsai |
Vaccines including antigen from four strains of influenza virus
|
KR100880298B1
(ko)
*
|
2006-12-06 |
2009-01-28 |
애나디스 파마슈티칼스, 인코포레이티드 |
3-β-D-리보푸라노실티아졸로[4,5-d]피리미딘뉴클레오시드 및 이의 용도
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
WO2008127613A1
(en)
*
|
2007-04-11 |
2008-10-23 |
Scynexis, Inc. |
New pharmaceutical compositions
|
EP2185191B1
(en)
|
2007-06-27 |
2012-09-12 |
Novartis AG |
Low-additive influenza vaccines
|
GB0713880D0
(en)
*
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
US20110166092A1
(en)
*
|
2007-08-20 |
2011-07-07 |
Anadys Pharmaceuticals, Inc. |
Dosing methods for treating disease
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
EP2268309B1
(en)
|
2008-03-18 |
2015-01-21 |
Novartis AG |
Improvements in preparation of influenza virus vaccine antigens
|
CN102083852A
(zh)
*
|
2008-06-06 |
2011-06-01 |
西尼克斯公司 |
环孢菌素类似物及其在治疗hcv感染中的应用
|
WO2009148615A1
(en)
*
|
2008-06-06 |
2009-12-10 |
Scynexis, Inc. |
Cyclosporin analogs and their use in the treatment of hcv infections
|
CN102307892A
(zh)
*
|
2008-12-31 |
2012-01-04 |
西尼克斯公司 |
环孢菌素a的衍生物
|
CA2754618A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
AU2010238255B2
(en)
|
2009-04-14 |
2014-10-16 |
Novartis Ag |
Compositions for immunising against Staphylococcus aureus
|
JP2012525370A
(ja)
|
2009-04-27 |
2012-10-22 |
ノバルティス アーゲー |
インフルエンザに対して防御するためのアジュバント添加ワクチン
|
MX2012000395A
(es)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Inmunogenos conservados de escherichia coli.
|
EP3178490B1
(en)
|
2009-07-15 |
2022-04-20 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
CA2768343A1
(en)
|
2009-07-16 |
2011-01-20 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
EP2509615A1
(en)
|
2009-12-09 |
2012-10-17 |
Scynexis, Inc. |
Novel cyclic peptides
|
US9173954B2
(en)
|
2009-12-30 |
2015-11-03 |
Glaxosmithkline Biologicals Sa |
Polysaccharide immunogens conjugated to E. coli carrier proteins
|
EP2575988A1
(en)
|
2010-05-28 |
2013-04-10 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
JP5909495B2
(ja)
|
2010-10-08 |
2016-04-26 |
ノバルティス アーゲー |
スルファミドns3阻害剤のビタミンe製剤
|
WO2012103361A1
(en)
|
2011-01-26 |
2012-08-02 |
Novartis Ag |
Rsv immunization regimen
|
CN102153548B
(zh)
*
|
2011-02-24 |
2012-11-28 |
河北大学 |
一种含有噻唑(嗪)烷酮环的类核苷衍生物及其制备方法和其在药物制剂中的应用
|
CN103842374A
(zh)
|
2011-05-13 |
2014-06-04 |
诺华股份有限公司 |
融合前的rsv f抗原
|
EP2718292B1
(en)
|
2011-06-03 |
2018-03-14 |
3M Innovative Properties Company |
Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
|
CN103582496B
(zh)
|
2011-06-03 |
2016-05-11 |
3M创新有限公司 |
具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
|
CN103764171B
(zh)
|
2011-07-08 |
2016-08-17 |
诺华股份有限公司 |
酪氨酸连接方法
|
EP2776069A1
(en)
|
2011-11-07 |
2014-09-17 |
Novartis AG |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
CN105307684A
(zh)
|
2012-10-02 |
2016-02-03 |
葛兰素史密丝克莱恩生物有限公司 |
非直链糖缀合物
|
PL2925355T3
(pl)
|
2012-11-30 |
2018-06-29 |
Glaxosmithkline Biologicals S.A. |
Antygeny pseudomonas i połączenia antygenów
|
PT2941233T
(pt)
|
2013-01-07 |
2020-11-13 |
Univ Pennsylvania |
Composições e métodos para tratar linfoma cutâneo de células t
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
CA2936377A1
(en)
|
2014-01-10 |
2015-07-16 |
Shanghai Birdie Biotech, Inc. |
Compounds and compositions for treating egfr expressing tumors
|
CN105440135A
(zh)
|
2014-09-01 |
2016-03-30 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
TWI727427B
(zh)
|
2014-07-09 |
2021-05-11 |
英屬開曼群島商博笛生物科技有限公司 |
用於治療腫瘤的抗pd-1組合
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
WO2017048807A1
(en)
|
2015-09-17 |
2017-03-23 |
Jrx Biotechnology, Inc. |
Approaches for improving skin hydration or moisturization
|
US10526309B2
(en)
|
2015-10-02 |
2020-01-07 |
The University Of North Carolina At Chapel Hill |
Pan-TAM inhibitors and Mer/Axl dual inhibitors
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
CN106943598A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-her2组合
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技(北京)有限公司 |
用于治疗肿瘤的抗-cd20组合
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
AU2017419352A1
(en)
|
2017-06-23 |
2019-12-12 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
BR112020016859A2
(pt)
|
2018-02-28 |
2020-12-29 |
Pfizer Inc. |
Variantes de il-15 e usos da mesma
|
WO2019224715A1
(en)
|
2018-05-23 |
2019-11-28 |
Pfizer Inc. |
Antibodies specific for cd3 and uses thereof
|
KR20230146098A
(ko)
|
2018-05-23 |
2023-10-18 |
화이자 인코포레이티드 |
GUCY2c에 특이적인 항체 및 이의 용도
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
US11702474B2
(en)
|
2019-12-17 |
2023-07-18 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
EP4182346A1
(en)
|
2020-07-17 |
2023-05-24 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
TW202345800A
(zh)
*
|
2022-04-06 |
2023-12-01 |
美商維納拓爾斯製藥公司 |
口服生物可利用的核苷類似物
|